Effect of Linagliptin on daily glucose excursion in Continuous Glucose Monitoring of Type2 diabetic patients
- Conditions
- Type 2 Diabetes
- Registration Number
- JPRN-UMIN000010880
- Lead Sponsor
- Japan society of Patient Reported Outcome
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
1.Type 1 and secondary diabetes 2.Severe infectious disease, before or after surgery, and severe trauma 3.Events of myocardial infarction, cerebral stroke, cerebral infarction and TIA in the past 3 month. 4.Moderate or severer heart failure(NYHA/New York Heart Association stage III or severer) 5.Severe liver dysfunction (ALT,AST and ALP face 3 times the normal level) 6.Past medical history of hypersensitivity to investigational drugs. 7.Patients addicted to alcohol and drugs. 8.Pregnant, lactating, and possibly pregnant women and those planning to become pregnant. 9.Patients with cancer. 10.Patent receiving steroid therapy with inflammatory affection. 11.Past medical history of abdominal operation and ileus. 12.Judged as ineligible by clinical investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of mean 24 hours glucose level at the point of 12 weeks from Baseline
- Secondary Outcome Measures
Name Time Method